The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime? Journal Article
| Authors: | Postow, M. A.; Callahan, M. K.; Wolchok, J. D. |
| Article Title: | The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime? |
| Abstract: | Ipilimumab has shown an overall survival benefit in 2 randomized phase III studies. A minority of patients achieve long-term disease control, highlighting the potential of this immunotherapeutic approach. In ongoing efforts, investigators are continuing to characterize these patients' unique clinical courses and correlate their responses with underlying mechanisms of antitumor immunity. ©2012 AACR. |
| Keywords: | cancer survival; treatment response; treatment duration; unspecified side effect; antineoplastic agent; glycoprotein gp 100; interleukin 2; ipilimumab; low drug dose; melanoma; antineoplastic combined chemotherapy protocols; antineoplastic activity; drug resistance; drug dose escalation; immunological tolerance; antibodies, monoclonal; immune response; immunotherapy; drug mechanism; immunogenicity; montanide isa 51; vaccination; drug response; tumor immunity; immunostimulation; immune deficiency; disease control; hla a antigen; immunopathology; lymphocyte count; tumor microenvironment; molecularly targeted therapy; ctla-4 antigen |
| Journal Title: | Clinical Cancer Research |
| Volume: | 18 |
| Issue: | 7 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2012-04-01 |
| Start Page: | 1821 |
| End Page: | 1823 |
| Language: | English |
| DOI: | 10.1158/1078-0432.ccr-12-0409 |
| PROVIDER: | scopus |
| PUBMED: | 22338019 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 May 2012" - "CODEN: CCREF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work